Q&A Genmab 2022-05-23

	23/5 13:37 af Jan Van de Winkel	Genmab is currently a magnet for talent and despite a challenging labour market, it is still hugely attractive for top-talent. We have never been in a better position to find new team members who all believe in a bright future with the company.
	23/5 13:37 af Sukkeralf	In a recent Medwatch article about the royalty loss to Janssen you said "..In the future, it will become clear why we didn’t chase an appeal...". Could you elaborate on what you mean by that sentence?
	23/5 13:38 af Jan Van de Winkel	No further comments.
	23/5 13:38 af Sukkeralf	Have Genmab/Janssen done any preclinical work with HexaCD38 compared to daratumumab in RA or solid tumors?
	23/5 13:39 af Jan Van de Winkel	No, such work has not been performed with HexaBody CD38. We are currently testing it clinically in MM.
	23/5 13:40 af Helge Larsen/PI-redaktør	Thank you for joining us and thank you for the many fullfilling answers to our questions. We look forward to seeing you back here on ProInvestor.com after Q2.
	23/5 13:40 af Jan Van de Winkel	We thoroughly our interaction and cannot wait for the next one.
	23/5 13:40 af Jan Van de Winkel	..
	23/5 13:40 af Jan Van de Winkel	Stay healthy and looking forward to speak soon.
	23/5 13:41 af Helge Larsen/PI-redaktør	This Q&A have ended.